Effect of supplemental oxygen on post-exercise inflammatory response and oxidative stress.
This investigation explored the influence of supplemental oxygen administered during the recovery periods of an interval-based running session on the post-exercise markers of reactive oxygen species (ROS) and inflammation. Ten well-trained male endurance athletes completed two sessions of 10 × 3 min running intervals at 85 % of the maximal oxygen consumption velocity (vVO(2)peak) on a motorised treadmill. A 90-s recovery period was given between each interval, during which time the participants were administered either a hyperoxic (HYP) (Fraction of Inspired Oxygen (FIO2) 99.5 %) or normoxic (NORM) (FIO2 21 %) gas, in a randomized, single-blind fashion. Pulse oximetry (SpO(2)), heart rate (HR), blood lactate (BLa), perceived exertion (RPE), and perceived recovery (TQRper) were recorded during each trial. Venous blood samples were taken pre-exercise, post-exercise and 1 h post-exercise to measure Interleukin-6 (IL-6) and Isoprostanes (F2-IsoP). The S(p)O(2) was significantly lower than baseline following all interval repetitions in both experimental trials (p < 0.05). The S(p)O(2) recovery time was significantly quicker in the HYP when compared to the NORM (p < 0.05), with a trend for improved perceptual recovery. The IL-6 and F2-IsoP were significantly elevated immediately post-exercise, but had significantly decreased by 1 h post-exercise in both trials (p < 0.05). There were no differences in IL-6 or F2-IsoP levels between trials. Supplemental oxygen provided during the recovery periods of interval based exercise improves the recovery time of SPO(2) but has no effect on post-exercise ROS or inflammatory responses.
School of Sport Science, Exercise and Health, The University of Western Australia, Crawley, Australia.
Jodii
J
White
Brian
B
Dawson
Grant
G
Landers
Kevin
K
Croft
Peter
P
Peeling
D000280:Administration, Inhalation; D000704:Analysis of Variance; D015415:Biomarkers / Q000097:blood; D005080:Exercise Test; D006339:Heart Rate; D006801:Humans; D018496:Hyperoxia / Q000097:blood / Q000150:complications* / Q000276:immunology / Q000503:physiopathology; D007249:Inflammation / Q000097:blood / Q000209:etiology* / Q000276:immunology / Q000503:physiopathology; D018836:Inflammation Mediators / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood; D028421:Isoprostanes / Q000097:blood; D019344:Lactic Acid / Q000097:blood; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D018384:Oxidative Stress / Q000187:drug effects*; D010092:Oximetry; D010100:Oxygen / Q000008:administration & dosage* / Q000097:blood; D010101:Oxygen Consumption; D010108:Oxyhemoglobins / Q000378:metabolism; D010465:Perception; D010807:Physical Endurance; D020127:Recovery of Function; D012420:Running; D016037:Single-Blind Method; D013997:Time Factors; D014904:Western Australia
D015415:Biomarkers; C508600:IL6 protein, human; D018836:Inflammation Mediators; D015850:Interleukin-6; D028421:Isoprostanes; D010108:Oxyhemoglobins; D019344:Lactic Acid; D010100:Oxygen